Fate Therapeutics (FATE) Total Debt (2012 - 2019)
Fate Therapeutics' (FATE) quarterly Total Debt came in at $13.9 million in Q3 2019, down 6.28% YoY from $14.9 million in Q3 2018, and down 6.6% on a QoQ basis from $14.9 million in Q2 2019.
Fate Therapeutics (FATE) Total Debt (2012 - 2019) Analysis & Trends
Fate Therapeutics (FATE) has 8 years of Total Debt data on file, last reported at $13.9 million in Q3 2019.
- Quarterly Total Debt fell 6.28% year-over-year to $13.9 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $13.9 million (down 6.28% YoY) and the FY2018 annual result came in at $14.9 million, up 0.51% from the prior year.
- Total Debt eased to $13.9 million in Q3 2019, from $14.9 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $19.7 million in Q2 2015 to a low of $6.7 million in Q2 2017.
- A 5-year average of $15.1 million and a median of $14.9 million in 2018 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2015 — Total Debt surged 2540.08% — and 2017, when it plunged 54.41%.
- Tracing FATE's Total Debt over 5 years: stood at $18.4 million in 2015, then sank by 41.84% to $10.7 million in 2016, then jumped by 38.55% to $14.8 million in 2017, then climbed by 0.51% to $14.9 million in 2018, then slipped by 6.4% to $13.9 million in 2019.
- The last three Total Debt figures came in at $13.9 million (Q3 2019), $14.9 million (Q2 2019), and $14.9 million (Q1 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 13.93 Mn |
| Jun 30, 2019 | 14.92 Mn |
| Mar 31, 2019 | 14.90 Mn |
| Dec 31, 2018 | 14.88 Mn |
| Sep 30, 2018 | 14.87 Mn |
| Jun 30, 2018 | 14.85 Mn |
| Mar 31, 2018 | 14.83 Mn |
| Dec 31, 2017 | 14.81 Mn |
| Sep 30, 2017 | 14.79 Mn |
| Jun 30, 2017 | 6.68 Mn |
| Mar 31, 2017 | 16.42 Mn |
| Dec 31, 2016 | 10.69 Mn |
| Sep 30, 2016 | 12.72 Mn |
| Jun 30, 2016 | 14.65 Mn |
| Mar 31, 2016 | 16.41 Mn |
| Dec 31, 2015 | 18.38 Mn |
| Sep 30, 2015 | 19.13 Mn |
| Jun 30, 2015 | 19.70 Mn |
| Mar 31, 2015 | 19.67 Mn |
| Dec 31, 2014 | 19.61 Mn |